Review of proliferative variables and their predictive value.

R. Silvestrini,M. Daidone

DOI: https://doi.org/10.1007/978-3-642-84745-5_10

Abstract:

What problem does this paper attempt to address?

A Specific and Sensitive Radioimmunoassay for Human Choriogonadotropin

K. Muralidhar,G. Chaudhuri,J. Lippes,O. P. Bahl

DOI: https://doi.org/10.1515/znc-1983-5-620

1983-06-01

Abstract:A specific and sensitive radioimmunoassay for human choriogonadotropin (hCG) has been developed using rabbit antiserum to chemical analogs of beta subunit of human chorionic gonadotropin prepared by controlled reduction and S-alkylation of its disulfide linkages. The assay was highly specific for hCG as the binding of [1251]-hCG to the antibody was not affected by standard human lutropin, by human male serum, postpartum serum from women, serum from post-menopausal women and human menopausal gonadotropin (Pergonal). The assay was highly sensitive, the minimal detection limit in terms of highly purified hCG (L-129, 12500 IU/mg) being 1 ng/ml or 0.2ng/tube (or 12mlU/ml in terms of WHO 2nd international reference preparation of hCG). Using this assay we were unable to detect any immunoreactive hCG in human tissues like lung, liver and colon. The high specificity, sensitivity, accuracy and reproducibility of the assay make this a highly desirable radioimmunoassay for human choriogonadotropin.
[Effect of the administration of Cardiostenol on experimental hepatitis in mice induced with MHV-3 virus].

V. Guadagnino,G. Borgia,A. Chirianni,R. Orlando,L. Picciotto,P. Tullio Cataldo,M. Piazza

1980-02-29

Abstract:Treatment with Cardiostenol (commercial name of a pharmaceutical product containing morphine chloridrate+atropine+sparteine) does not modify the course of hepatitis in mice infected with MHV-3 virus. Similar results were previously obtained by treatment with morphine chloridrate alone.
A case of early diagnosed carnitine deficiency presenting with respiratory symptoms

Muferet Erguven,Oznur Yilmaz,Seher Koc,Suar Caki,Yusuf Ayhan,Metin Donmez,Gulderen Dolunay

DOI: https://doi.org/10.1159/000107675

Abstract:Introduction: Carnitine deficiency is an autosomal recessively inherited disease characterized by a low carnitine concentration in plasma and tissues. Primary carnitine deficiency (PCD) is caused by a deficiency in the plasma membrane carnitine transporter, with urinary carnitine wasting causing systemic carnitine depletion. The most common presentation of PCD is hypoketotic hypoglycemic encephalopathy. Cardiomyopathy can also be seen. Case report: A 9-month-old girl was admitted to our clinic with wheezing, respiratory distress and nighttime cough. She was pale, expirium was prolonged, breath sounds were coarse bilaterally and were increased in the right hemithorax. Results: She had hypochromic microcytic anemia and the serum CPK level was elevated. Cardiothoracic index was increased (0.62). In the chest X-ray there was hyperaeration especially in the upper regions of the left lung, and paracardiac infiltration in the right lung. The echocardiogram showed dilated cardiomyopathy. In pulmonary perfusion scintigraphy, perfusion of the right lung was 26% and of the left lung 74%. Cardiomegaly and dilatation in main the pulmonary artery was detected in the MR angiogram. Plasma carnitine and acylcarnitine levels were found to be significantly low. Fat accumulation in myocytes and rare atrophic fibers were detected in a muscle biopsy. Oral carnitine supplementation was started at a dose of 100 mg/kg. All the symptoms and findings regressed within a short period of time. Discussion: This case was presented to emphasize that carnitine deficiency can present with respiratory tract symptoms like wheezing and recurrent respiratory tract infections. Although PCD usually presents with hypoketotic hypoglycemia in infants, it also has to be suspected in the etiology of dilated cardiomyopathy. Treatment is very easy and lifesaving once the correct diagnosis is made, and the prognosis is excellent with lifelong carnitine supplementation.
Diagnostic Challenges in the Myopathic Variant of Carnitine Palmitoyltransferase II Deficiency: A Case Report

Lana Alabbasi,Hadhami Ben Turkia,Maram Nass,Ibrahim Sahin

DOI: https://doi.org/10.7759/cureus.64728

2024-07-17

Cureus

Abstract:Carnitine palmitoyltransferase II deficiency is a rare metabolic disorder affecting the mitochondrial oxidation of fatty acids. We present a case of the myopathic form in a 10-year-old Bahraini male following an initial presentation of exercise-induced rhabdomyolysis and transaminitis. There was no consanguinity or findings suggestive of an underlying inborn metabolic disorder. Tandem mass spectrometry on dried blood spots showed no abnormal acyl-carnitines profile. The condition improved with hyperhydration, high glucose intake, carnitine, and alkalinization. Genetic testing revealed a compound heterozygous pathogenic variant c.338C>T (p.Ser113Leu) and a variant of unknown significance c.729_731del (p.Leu244del). The patient was kept on a high carbohydrate and low-fat diet with medium chain triglycerides supplementation and advised to avoid long fasting periods and strenuous exercise. Within the four years of follow-up, he had three further attacks. Exercise-induced myalgia or rhabdomyolysis should raise the suspicion of inherited metabolic disorders. Metabolic investigations should be taken during the acute illness, and an acylcarnitines profile should preferably be performed in the serum.
Metformin, valproic acid, and starvation induce seizures in a patient with partial SLC13A5 deficiency: a case of pharmaco-synergistic heterozygosity

Jonathan Kopel,Amy Grooms,Vadivel Ganapathy,Jeffrey Clothier

DOI: https://doi.org/10.1097/YPG.0000000000000269

2021-02-01

Abstract:SLC13A5/NaCT is a sodium-coupled citrate transporter expressed in the plasma membrane of the liver, testis, and brain. In these tissues, SLC13A5 has important functions in the synthesis of fatty acids, cholesterol, and neurotransmitters. In recent years, patients homozygous for recessive mutations in SLC13A5, known as SLC13A5 deficiency [early infantile epileptic encephalopathy-25 (EIEE-25)], exhibit severe global developmental delay, early-onset intractable seizures, spasticity, and amelogenesis imperfecta affecting tooth development. Although the pathogenesis of SLC13A5 deficiency remains not clearly understood, cytoplasmic citrate deficits, decreased energy status in neurons, and citrate-zinc chelation are hypothesized to explain the neurological deficits. However, no study has examined the possibility of specific pharmacological drugs and/or lifestyle changes synergizing with heterozygosity of SLC13A5 deficiency to increase the risk of EIEE-25 clinical phenotype. Here, we report on a heterozygous SLC13A5-deficient patient who demonstrated evidence of pharmaco-synergistic heterozygosity upon administration of metformin, valproic acid, and starvation. The report illustrates the importance of careful consideration of the potential adverse effects of specific pharmacological treatments in patients with heterozygosity for disease-causing recessive mutations in SLC13A5.
Familial Hyperinsulinism-Hyperammonemia Syndrome in a Family with Seizures: Case Report

Javier de las Heras,Intza Garin,Guiomar Perez de Nanclares,Anibal Aguayo,Itxaso Rica,Luis Castaño,Amaia Vela

DOI: https://doi.org/10.1515/jpem.2010.132

2010-01-01

Journal of Pediatric Endocrinology and Metabolism

Abstract:Hyperinsulinism-hyperammonemia (HI/HA) syndrome is the second most frequent cause of congenital hyperinsulinism (CHI) and it is characterized by recurrent symptomatic hypoglycemia and persistent hyperammonemia. We describe the familial case of a 2-year-old child and her 32-year-old mother who, having suffered from tonic-clonic seizures since infancy, had both been diagnosed with epilepsy and treated with sodium valproate. Hypoglycemia was identified in the child in routine analysis. Six days after admission, a complete study of hypoglycemia showed test results compatible with hyperinsulinemic hypoglycemia and hyperammonemia. A mutation in the GDH gene (Arg269His) confirmed the diagnosis in both the mother and the child. An important peculiarity of this case is the diagnosis of a 32-year-old woman, previously diagnosed with epilepsy through her daughter's diagnosis at a Pediatric Endocrinology Department and subsequently treated ineffectively with sodium valproate. We conclude that, as hypoglycemia may be subtle, the diagnosis of HI/HA should be considered in children or adults with seizures/epilepsy and hyperammonemia, serum ammonia being a simple screening test for the disease.

pediatrics,endocrinology & metabolism
Disorders of Consciousness after Subacute Stroke Might Partly be Caused by Carnitine Deficiency: Two Case Reports

Makoto Ueno,Seiji Miura,Rintaro Ohama,Megumi Shimodozono

DOI: https://doi.org/10.2490/prm.20230019

2023-06-29

Abstract:Background: Carnitine is a vital human nutrient. Although there are many reports on carnitine deficiency, most studies have been conducted on children, patients with severe mental and physical disabilities, epileptic patients, patients with liver cirrhosis, and dialysis patients. To the best of our knowledge, there are no reports on carnitine administration for disorders of consciousness after stroke. We report two such cases in which carnitine administration improved disorders of consciousness. Cases: Case 1 was a woman in her sixties who was admitted to our rehabilitation center 4 months after the onset of subarachnoid hemorrhage. After admission, her disorders of consciousness worsened even though she was actively undergoing rehabilitation. Suspecting carnitine deficiency, we administered 1500 mg/day of L-carnitine, which resulted in improvement of her disorders of consciousness and disappearance of symptoms such as convulsions. Case 2 was a man in his thirties who was admitted to our rehabilitation center 5 months after the onset of cerebral hemorrhage. During active rehabilitation, he suffered worsening disorders of consciousness, convulsions, and cramps. We found carnitine deficiency with a blood carnitine concentration of 21 mg/dL, so we administered 1500 mg/day of L-carnitine; symptoms of disorders of consciousness and convulsions then improved. Discussion: It is possible that carnitine deficiency has been overlooked in some patients in rehabilitation wards, and measurement of ammonia might facilitate its detection. Because carnitine deficiency can interfere with active rehabilitation, nutritional management with attention to carnitine deficiency could be important during rehabilitation.
Two Patients Diagnosed as Succinate Dehydrogenase Deficiency: Case Report

Burcu Civelek Ürey,Ahmet Cevdet Ceylan,Büşranur Çavdarlı,Ayşegül Neşe Çıtak Kurt,Oya Kıreker Köylü,Burak Yürek,Çiğdem Seher Kasapkara

DOI: https://doi.org/10.1159/000527538

Abstract:Introductıon: Succinate dehydrogenase deficiency, also known as mitochondrial complex II deficiency, is a rare inborn error of metabolism, accounting for approximately 2% of mitochondrial disease. Mutations in the four genes SDHA, B, C,and D have been reported resulting in diverse clinical presentations. The vast majority of clinically affected individuals reported in the literature harbor genetic variants within the SDHA gene and present with a Leigh syndrome phenotype, clinically defined as a subacute necrotizing encephalopathy. Case report: Herein, we report the first case of a 7-year-old child who was diagnosed as having succinate dehydrogenase deficiency. The affected child presented at 1 year of age with encephalopathy and developmental regression following viral illnesses. MRI changes supported a clinical diagnosis of Leigh syndrome and c.1328C>Q and c.872A>C SDHA variants were identified as compound heterozygous. Mitochondrial cocktail treatment including L-carnitine, riboflavin, thiamine, biotin, and ubiquinone was started. Mild clinical improvement was observed after treatment. He is now unable to walk and speak. The second patient, a 21-year-old woman, presented with generalized muscle weakness, easy fatigability, and cardiomyopathy. Investigations revealed increased lactate level of 67.4 mg/dL (4.5-19.8) with repeatedly increased plasma alanine levels 1,272 µmol/L (200-579). We administered carnitine, coenzyme, riboflavin, and thiamine for empirical therapy with the suspicion of mitochondrial disease. Clinical exome sequencing revealed compound heterozygous variants NM_004168.4:c.1945_1946del (p.Leu649GlufsTer4) at exon 15 of the SDHA gene and NM_004168.4:c.1909-12_1909-11del at intron 14 of SDHA gene. Discussion and conclusion: There are several very different presentations including Leigh syndrome, epileptic encephalopathy, and cardiomyopathy. Some cases present following viral illness; this feature is not specific to mitochondrial complex II deficiency and occurs in many other mitochondrial disease presentations. There is no cure for complex II deficiency, though some reported patients showed clinical improvement following riboflavin therapy. Riboflavin is not the only therapeutic intervention that is available to patients with an isolated complex II deficiency and various other compounds have shown promise in the treatment of symptoms, including L-carnitine and ubiquinone. Treatment alternatives such as parabenzoquinone EPI-743 and rapamycin are under study in the treatment of the disease.
A report of a pedigree with compound heterozygous mutations in the SLC22A5 gene

Yunguo Zhou,Yucai Liu,Yang Shen,Fang Xu,Fei Xu,Hui Huang,Junkai Duan

DOI: https://doi.org/10.3389/fped.2023.985720

IF: 3.569

2023-06-06

Frontiers in Pediatrics

Abstract:Introduction: To investigate the clinical characteristics and disease outcomes of a pedigree with compound heterozygous mutations in the SLC22A5 gene. Methods: Serum acylcarnitine profiles of patients were analyzed using tandem mass spectrometry. DNA samples isolated from patients and their first-degree relatives were subjected to high-throughput sequencing, and mutations were validated using Sanger sequencing. Results: The proband, a 4-month-old girl, presented with seizure episodes and mild cardiac hypertrophy and was diagnosed with primary carnitine deficiency (PCD), with carnitine levels of 5.165 mol/L. Her brother, a 6-year-and 4-month-old boy, was also diagnosed with PCD with serum-free carnitine levels of 1.014 mol/L (reference values 10–60 mol/L). Compound heterozygous mutations (c.760C > T [p.R254X] and c.825G > A [p.W275X]) were detected in the SLC22A5 gene in both patients and were inherited from the mother and father, respectively. Oral L-carnitine significantly improved or resolved the clinical symptoms. Conclusion: Children with compound mutations in SLC22A5 may present different clinical manifestations, particularly at different ages. Early clinical manifestations have a greater impact on the organs and may cause irreversible damage. PCD can cause epilepsy and dilated cardiomyopathy. Tandem mass spectrometry and high-throughput sequencing are recommended to confirm the diagnosis. Early L-carnitine supplementation can improve symptoms and reverse organ damage in some children. Tandem mass spectrometry should be used to screen for newborns with a family history of PCD.

pediatrics
Neuraxial labor analgesia in a parturient with carnitine palmitoyl transferase type II deficiency: a case report

T K Bowman,A Oweidat,N El Hage Chehade,M Cheriyan,S Ayad,M Hoyt

DOI: https://doi.org/10.1016/j.ijoa.2024.104246

2024-08-08

Abstract:Carnitine Palmitoyl Transferase Type II (CPT II) deficiency is a disorder of fatty acid beta oxidation that causes decreased adenosine triphosphate (ATP) and ketone production during periods of fasting or high energy requirements. Labor and delivery can precipitate attacks for parturients with this disorder, causing hypoglycemia, muscle weakness, rhabdomyolysis, and kidney failure. Anesthetic management considers the delivery mode and anesthetic medications available to reduce these risks. We present the case of a pregnant patient with CPT II deficiency with labor epidural analgesia and a vaginal delivery, with alternative plans had a different delivery mode been required.
Secondary Carnitine Deficiency in Neonates and Infants Requiring Surgery for Intestinal Obstructions—An Underestimated and Undermanaged Problem

Sheng-Yang Huang,Chia-Man Chou,Hou-Chuan Chen

DOI: https://doi.org/10.3390/children11020147

2024-01-24

Children

Abstract:This study aims to elucidate the relationship between intestinal obstruction and carnitine deficiency in neonates and infants. We retrospectively reviewed medical records of 330 neonates and infants, younger than six months, who underwent surgery for intestinal obstruction at our institute from January 2009 to April 2022. The analysis focused on clinical symptoms, related signs, complications, and etiology of the intestinal obstruction. Tandem mass spectrometry (MS/MS) or urine organic acid analysis was conducted for 47 patients, revealing carnitine deficiency in 16 patients. The incidence of carnitine deficiency was 34.0% in the suspicious group and 4.8% overall, significantly higher than in the general population in Taiwan. Notably, patients with carnitine deficiency experienced prolonged ileus, with a mean fasting duration of 41.7 days (range 7.8–65.5 days), compared to 10.8 days (range 8.2–13.4 days) in patients without carnitine deficiency. Carnitine replacement therapy was administered to twelve patients at dosages ranging from 32 to 90 mg/kg/day. One patient exhibited a drug allergy with skin rashes. Our findings suggest that carnitine deficiency should be considered in cases of neonatal and infant intestinal obstruction. Replacement therapy is straightforward and can be prognostically beneficial for some patients. Therefore, we recommend generalizing MS/MS and urine organic acid analysis, particularly for patients with prolonged ileus.

pediatrics
Severe Gastroparesis Leading to Hypoglycemia and Subsequent Seizures

Nardine Abdelsayed,Angel Juarez,Mary Carter

DOI: https://doi.org/10.7759/cureus.30527

2022-10-20

Cureus

Abstract:Gastroparesis is a known complication in patients with diabetes mellitus (DM). This disorder has been known to make glycemic control difficult due to diabetic autonomic neuropathy, resulting in an increase in hypoglycemic episodes. On occasion, gastroparesis may be so severe that prokinetic medications and gastric pacemakers are not sufficient to control the symptoms, in which case some patients need to supplement their diet through a jejunal tube (J-tube) to bypass the stomach. Severe or long-lasting hypoglycemia may rarely be associated with epileptic seizures. We present a case of a 47-year-old female with a history significant for type 1 DM complicated by gastroparesis requiring a gastric pacemaker and J-tube placement who presented to the emergency department after having a witnessed seizure. Her glucose at that time was 27 mg/dl (normal 70-110 mg/dl) and she was treated appropriately with dextrose 25% solution and her glucose recovered to 110 mg/dl. Subsequently, seizure activity ceased.
Ketogenic Diet Treatment of Defects in the Mitochondrial Malate Aspartate Shuttle and Pyruvate Carrier

Bigna K. Bölsterli,Eugen Boltshauser,Luigi Palmieri,Johannes Spenger,Michaela Brunner-Krainz,Felix Distelmaier,Peter Freisinger,Tobias Geis,Andrea L. Gropman,Johannes Häberle,Julia Hentschel,Bruno Jeandidier,Daniela Karall,Boris Keren,Annick Klabunde-Cherwon,Vassiliki Konstantopoulou,Raimund Kottke,Francesco M. Lasorsa,Christine Makowski,Cyril Mignot,Ruth O'Gorman Tuura,Vito Porcelli,René Santer,Kuntal Sen,Katja Steinbrücker,Steffen Syrbe,Matias Wagner,Andreas Ziegler,Thomas Zöggeler,Johannes A. Mayr,Holger Prokisch,Saskia B. Wortmann

DOI: https://doi.org/10.3390/nu14173605

IF: 5.9

2022-09-01

Nutrients

Abstract:The mitochondrial malate aspartate shuttle system (MAS) maintains the cytosolic NAD+/NADH redox balance, thereby sustaining cytosolic redox-dependent pathways, such as glycolysis and serine biosynthesis. Human disease has been associated with defects in four MAS-proteins (encoded by MDH1, MDH2, GOT2, SLC25A12) sharing a neurological/epileptic phenotype, as well as citrin deficiency (SLC25A13) with a complex hepatopathic-neuropsychiatric phenotype. Ketogenic diets (KD) are high-fat/low-carbohydrate diets, which decrease glycolysis thus bypassing the mentioned defects. The same holds for mitochondrial pyruvate carrier (MPC) 1 deficiency, which also presents neurological deficits. We here describe 40 (18 previously unreported) subjects with MAS-/MPC1-defects (32 neurological phenotypes, eight citrin deficiency), describe and discuss their phenotypes and genotypes (presenting 12 novel variants), and the efficacy of KD. Of 13 MAS/MPC1-individuals with a neurological phenotype treated with KD, 11 experienced benefits—mainly a striking effect against seizures. Two individuals with citrin deficiency deceased before the correct diagnosis was established, presumably due to high-carbohydrate treatment. Six citrin-deficient individuals received a carbohydrate-restricted/fat-enriched diet and showed normalisation of laboratory values/hepatopathy as well as age-adequate thriving. We conclude that patients with MAS-/MPC1-defects are amenable to dietary intervention and that early (genetic) diagnosis is key for initiation of proper treatment and can even be lifesaving.

nutrition & dietetics
Model for oxygen transfer in rotating biological contactor.

V. Kubsad,Sanjeev Chaudhari,S. Gupta

DOI: https://doi.org/10.1016/J.WATRES.2004.08.016

IF: 12.8

2004-12-01

Water Research

Abstract:
PSUN338 A 2 year-old Girl with a Congenital Portosystemic Shunt and Hypoglycemia Due to Secondary Hyperinsulinism Treated with Uncooked Cornstarch

Timothy Foster,Angelina Bernier

DOI: https://doi.org/10.1210/jendso/bvac150.863

2022-11-01

Journal of the Endocrine Society

Abstract:Abstract Background Hepatic portosystemic shunts (Abernethy malformation) are rare congenital malformations in children, which result in direct connections of splanchnic venous drainage to systemic circulation, bypassing hepatic uptake and metabolism. Congenital portosystemic shunts (CPSS) can also rarely lead to secondary hyperinsulinism and hypoglycemia. We describe a case of a 2-year-old girl with a CPSS presenting with hypoglycemia due to reactive hyperinsulinism successfully treated with uncooked cornstarch. Clinical Case A 2-year-old girl presents for evaluation of altered mental status and hypoglycemia. Three months earlier she was treated for Lemierre syndrome and found to have a CPSS (severely hypoplastic portal vein with direct drainage of splanchnic vasculature into the IVC) with hyperammonemia treated with lactulose and rifaximin. This admission, she presented with lethargy and altered mental status as she was difficult to arouse. EMS detected a glucose of 19 mg/dl and treated her with a bolus of 25% dextrose fluids. The day before, she had eaten a typical dinner of cookies and mashed potatoes without concern. On admission, she had no elevation in urine ketones and her blood gas measurements, alcohol, and ammonia levels were within normal limits, as such a diagnosis of secondary hyperinsulinism was suspected. A 3-hour OGTT with 2 g/kg glucose was performed after 2 days of stable oral intake and normoglycemia. Her fasting glucose was 74 mg/dl with a baseline insulin of 9.3 mcIU/ml. Within 1 hour, her glucose rose to 223 mg/dl with an insulin of 247.14 mcIU/ml. At 3 hours (2-hour levels not obtained) her glucose dropped to 67 mg/dl and with an insulin of 24.83 mcIU/ml. Thirty minutes after completion of the OGTT (3.5 hours from glucose load) she became lethargic with a glucose of 45 mg/dl confirming suspicion for secondary hyperinsulinism induced hypoglycemia. Education on glucose monitoring, hypoglycemia management and dietary changes were made to include meals with sufficient fat and protein to help reduce postprandial hyperglycemia. Additionally, uncooked cornstarch 1.4 g/kg was started to provide an overnight source of carbohydrates while avoiding rapid absorption. At 3 months her mother reported no hypoglycemic episodes with fasting glucose levels 80-100 mg/dl. Clinical Lessons Hypoglycemia can occur in CPSS patients due to secondary hyperinsulinism. The vascular malformation causes postprandial hyperglycemia, from the absence of first-pass uptake of glucose by the liver, which leads to insulin secretion. However, insulin similarly bypasses hepatic uptake and degradation after release (normally clears up to 80% of insulin), and the systemic circulation and peripheral tissues are exposed to elevated levels leading to hypoglycemia. While surgical correction provides definitive treatment, uncooked cornstarch can maintain euglycemia both by decreasing postprandial hyperglycemia and by providing a slowly absorbed source of carbohydrate. Presentation: Sunday, June 12, 2022 12:30 p.m. - 2:30 p.m.
Cerebral folate deficiency: a treatable cause of late deterioration in epilepsy with developmental delay

Fahmida Amin Chowdhury,Elisaveta Sokolov,Jessica Anderson,Dragana J Josifova,Lina Nashef

DOI: https://doi.org/10.1136/pn-2023-003727

2024-01-23

Abstract:A 25-year-old woman with childhood-onset refractory epilepsy and developmental delay experienced a gradually progressive marked deterioration in mobility and seizure control, with language regression. Investigation identified a homozygous deletion within the contactin-associated protein-like 2 gene (CNTNAP2), underlying her early presentation, but also cerebral folate deficiency that most likely contributed to her later deterioration. Following antiseizure medication adjustment and treatment with folinic acid, she stabilised with improved seizure control and limited improvement in language and motor function; she has remained neurologically stable for more than a decade. That the previously observed neurological decline was halted by folinic acid replacement supports this being due to cerebral folate deficiency. Metabolic conditions are less well recognised in adults and can be under-diagnosed. They are potentially treatable and should be considered even in the presence of another cause, particularly when the presentation is not fully compatible.
Altered Serum Amino Acid and Acylcarnitine Profiles in Hyperinsulinemic Hypoglycemia and Ketotic Hypoglycemia

Zhen-Ran Xu,Xiao-Yi Zhu,Wei Lu,Wei-Hua Sun,Ruo-Qian Cheng,Jin-Wen Ni,Li Xi,Khalid Hussain,Fei-Hong Luo,Miao-Ying Zhang

DOI: https://doi.org/10.3389/fendo.2020.577373

IF: 6.055

2020-10-08

Frontiers in Endocrinology

Abstract:Background: In addition to inborn metabolic disorders, altered metabolic profiles were reported to be associated with the risk and prognosis of some non-metabolic diseases, while as a rare metabolic disease, the overall secondary metabolic spectrum in congenital hyperinsulinemic hypoglycemia (HH) is largely undetermined. Therefore, we investigated metabolic profiles in HH patients and used ketotic hypoglycemia (KH) patients as a control cohort to unveil their distinct metabolic features.Methods: A total of 97 hypoglycemia children, including 74 with hyperinsulinemic hypoglycemia and 23 with ketotic hypoglycemia, and 170 euglycemia control subjects were studied retrospectively. Clinical and biochemical data were collected. The normoglycemic spectra of amino acids and acylcarnitines were determined by liquid chromatography tandem mass spectrometry. The serum insulin and fatty acid concentrations during standardized fasting tests in hypoglycemia patients were also collected. Receiver operating characteristic curve analysis was performed to screen potential biomarkers.Results: Among the normoglycemic spectra of amino acids, blood valine (p < 0.001), arginine (p < 0.001), threonine (p = 0.001), glutamate (p = 0.002), methionine (p = 0.005), ornithine (p = 0.008), leucine (p = 0.014), alanine (p = 0.017), proline (p = 0.031), citrulline (p = 0.042), aspartate (p = 0.046), and glycine (p = 0.048) levels differed significantly among the three groups. Significantly decreased levels of long- (C14:1, p < 0.001; C18, p < 0.001), medium- (C8, p < 0.001; C10, p < 0.001; C10:1, p < 0.001), and short-chain (C4-OH, p < 0.001; C5OH, p < 0.001) acylcarnitines were found in the hyperinsulinemic hypoglycemia group. Hyperinsulinemic hypoglycemia children with focal lesions and diffuse lesions had similar amino acid and acylcarnitine spectra. C10:1 < 0.09 μmol/L, threonine > 35 μmol/L, and threonine/C10:1 > 440 showed sensitivities of 81.1, 66.2, and 81.1% and specificities of 72.7, 78.3, and 81.8%, respectively, in distinguishing HH from KH.Conclusions: We found significantly different altered serum amino acid and acylcarnitine profiles at normoglycemia, especially decreased C10:1 and increased threonine levels, between HH and KH children, which may reflect the insulin ketogenesis inhibition effect in HH patients; however, the detailed mechanisms and physiological roles remain to be studied in the future.

endocrinology & metabolism
Mitochondrial HMG-CoA Synthase Deficiency: A Cyclic Vomiting Mimic Without Reliable Biochemical Markers

Annie D Niehaus,Holly Cooper,Chung U Lee

DOI: https://doi.org/10.1177/23247096241267154

Abstract:Here, we report an individual, eventually diagnosed with HMG-CoA synthase deficiency, who presented with a cyclic vomiting phenotype. HMG-CoA synthase deficiency is a rare disorder affecting ketone body synthesis in which affected individuals typically present at a young age with hypoketotic hypoglycemia, lethargy, encephalopathy, and hepatomegaly, usually triggered by catabolism (e.g., infection or prolonged fasting). This individual presented with recurrent episodes of vomiting and lethargy, often associated with hypoglycemia or hyperglycemia, at 3 years of age. Metabolic labs revealed nonspecific abnormalities in her urine organic acids (showing mild elevation of dicarboxylic acids with relatively low excretion of ketones) and a normal acylcarnitine profile. Given her clinical presentation, as well as a normal upper gastrointestinal series, esophagogastroduodenoscopy with biopsies, and abdominal ultrasound, she was diagnosed with cyclic vomiting syndrome at 3 years of age. Molecular testing completed at 7 years of age revealed a previously reported pathogenic sequence variant (c.1016+1G>A) and a novel likely pathogenic deletion (1.57 kB deletion, including exon 1) within HMGCS2 consistent with HMG-CoA synthase deficiency. This individual's presentation, mimicking cyclic vomiting syndrome, widens the clinical spectrum of HMG-CoA synthase deficiency. In addition, this case highlights the importance of molecular genetic testing in such presentations, as this rare disorder lacks specific metabolic markers.
Metabolic etiologies in children with infantile epileptic spasm syndrome: Experience at a tertiary pediatric neurology center

Merve Feyza Yüksel,Neslihan Doğulu,Miraç Yıldırım,Engin Köse,Ömer Bektaş,Fatma Tuba Eminoğlu,Serap Teber

DOI: https://doi.org/10.1016/j.braindev.2024.03.003

IF: 2.272

2024-03-17

Brain and Development

Abstract:Objective Infantile epileptic spasm syndrome (IESS), including West syndrome (WS) and infantile spasm (IS), causes a challenging prognosis, particularly when associated with metabolic etiologies. Methods This study, conducted at a tertiary pediatric neurology center, explored the prevalence and clinical features of inborn errors of metabolism in 112 children with IESS over 10 years. Results Most patients presented with seizures, primarily flexor spasms, and the median age at onset was 5 months. Comprehensive clinical evaluation and neuroimaging revealed structural-acquired causes as the most common etiology. Notably, inborn errors of metabolism were identified in 5.4 % of cases, with six distinct diagnoses including nonketotic hyperglycinemia, pyridoxine-dependent epilepsy, primary coenzyme Q10 deficiency 7, congenital disorder of glycosylation type IIM, 6-pyruvoyl tetrahydrobiopterin synthase deficiency, and argininosuccinate lyase deficiency. The prevalence of inborn errors of metabolism in this cohort was consistent with global variations reported in the literature. Genetic testing, including karyotype analysis and whole exome sequencing, was performed in a subset of cases with no clear diagnosis, revealing abnormalities in approximately 50 % of cases. Adrenocorticotropic hormone emerged as the most frequently prescribed antiseizure medication. Conclusion This study provides insight into the diagnostic challenges associated with IESS and highlights the importance of metabolic investigations, especially in cases without a clear etiology. The findings emphasize the need for further genetic and metabolic studies to enhance prognostic accuracy and guide potential treatment options for children with IESS, particularly in populations with high rates of consanguinity.

pediatrics,clinical neurology
Insulin therapy in acute decompensation of holocarboxylase synthetase deficiency with hyperglycemia and ketoacidosis

Tanguy Demaret,Jean-Sébastien Joyal,Aspasia Karalis,Fabienne Parente,Marie-Ange Delrue,Grant A. Mitchell

DOI: https://doi.org/10.1016/j.ymgmr.2024.101073

IF: 2.082

2024-03-23

Molecular Genetics and Metabolism Reports

Abstract:An 11-month-old girl with severe acidosis, lethargy and vomiting, was diagnosed with holocarboxylase synthetase deficiency. She received biotin and was stable until age 8 years when vomiting, severe acidosis, hypoglycemia, and hyperammonemia developed. Management with intravenous glucose aiming to stimulate anabolism led to hyperglycemic ketoacidosis. Insulin therapy rapidly corrected biochemical parameters, and clinical status improved. We propose that secondary Krebs cycle disturbances affecting pancreatic beta cells impaired glucose-stimulated insulin secretion, resulting in insulinopenia.

genetics & heredity

Review of proliferative variables and their predictive value.

A Specific and Sensitive Radioimmunoassay for Human Choriogonadotropin

[Effect of the administration of Cardiostenol on experimental hepatitis in mice induced with MHV-3 virus].

A case of early diagnosed carnitine deficiency presenting with respiratory symptoms

Diagnostic Challenges in the Myopathic Variant of Carnitine Palmitoyltransferase II Deficiency: A Case Report

Metformin, valproic acid, and starvation induce seizures in a patient with partial SLC13A5 deficiency: a case of pharmaco-synergistic heterozygosity

Familial Hyperinsulinism-Hyperammonemia Syndrome in a Family with Seizures: Case Report

Disorders of Consciousness after Subacute Stroke Might Partly be Caused by Carnitine Deficiency: Two Case Reports

Two Patients Diagnosed as Succinate Dehydrogenase Deficiency: Case Report

A report of a pedigree with compound heterozygous mutations in the SLC22A5 gene

Neuraxial labor analgesia in a parturient with carnitine palmitoyl transferase type II deficiency: a case report

Secondary Carnitine Deficiency in Neonates and Infants Requiring Surgery for Intestinal Obstructions—An Underestimated and Undermanaged Problem

Severe Gastroparesis Leading to Hypoglycemia and Subsequent Seizures

Ketogenic Diet Treatment of Defects in the Mitochondrial Malate Aspartate Shuttle and Pyruvate Carrier

Model for oxygen transfer in rotating biological contactor.

PSUN338 A 2 year-old Girl with a Congenital Portosystemic Shunt and Hypoglycemia Due to Secondary Hyperinsulinism Treated with Uncooked Cornstarch

Cerebral folate deficiency: a treatable cause of late deterioration in epilepsy with developmental delay

Altered Serum Amino Acid and Acylcarnitine Profiles in Hyperinsulinemic Hypoglycemia and Ketotic Hypoglycemia

Mitochondrial HMG-CoA Synthase Deficiency: A Cyclic Vomiting Mimic Without Reliable Biochemical Markers

Metabolic etiologies in children with infantile epileptic spasm syndrome: Experience at a tertiary pediatric neurology center

Insulin therapy in acute decompensation of holocarboxylase synthetase deficiency with hyperglycemia and ketoacidosis